Tumor-stroma type and tumor-stroma ratio predict neoadjuvant chemotherapy response in breast cancer
An effective risk analysis for neoadjuvant chemotherapy treatment is not always possible with current clinicopathological parameters. Tumor-stroma ratio and tumor-stroma type seem useful in predicting neoadjuvant chemotherapy response as a reproducible practical marker and do not require additional cost and time.
Authors
- Nazlıcan Yalçın (ORCID: https://orcid.org/0009-0002-3537-614X)
- Anıl Can Yalçın (ORCID: https://orcid.org/0009-0000-6474-2474)
- Oğuzhan Okçu (ORCID: https://orcid.org/0000-0001-7481-4718)
- Çiğdem Öztürk (ORCID: https://orcid.org/0000-0003-2587-214X)
- Bayram Şen (ORCID: https://orcid.org/0000-0002-4541-881X)
- Ezgi Hacıhasanoğlu (ORCID: https://orcid.org/0000-0002-6661-1002)
- Esra Aydın (ORCID: https://orcid.org/0000-0003-0210-3153)
Institutions
- Yeditepe University (TR)
- Recep Tayyip Erdoğan University (TR)
Publication Details
- Journal
- Revista da Associação Médica Brasileira
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1590/1806-9282.20241225
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.87